中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 天然药物化学研究室
Synthesis and antitumor activity of novel salvicine analogues

文献类型：期刊论文

作者Deng, Fei1; Lu, Jin Jian1; Liu, Hong Ying2; Lin, Li Ping1; Ding, Jian1; Zhang, Jin Sheng1
刊名CHINESE CHEMICAL LETTERS
出版日期2011-01
卷号22期号:1页码:25-28
关键词Saprorthoquinone Salvicine Antitumor Structural modification
ISSN号1001-8417
DOI10.1016/j.cclet.2010.07.009
文献子类Article
英文摘要Systematic structure modification of the side train of the lead compound saprothoquinone provides a series of salvicine analogues, fifteen of them were first reported. Some compounds were demonstrated potent cytotoxicity against tumor cells with the 50% inhibition concentration in the micromolar range. Furthermore some compounds showed potent topoisomerase II inhibitory effects. The preliminary structure-activity relationship of saprorthoquinone analogues was discussed according to their cytotoxicity against three tumor cells. (C) 2010 Fei Deng. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.
WOS关键词PRIONITIS
WOS研究方向Chemistry
语种英语
CSCD记录号CSCD:4122330
WOS记录号WOS:000286551700007
出版者ELSEVIER SCIENCE INC
源URL[http://119.78.100.183/handle/2S10ELR8/278632]  
专题天然药物化学研究室
中科院受体结构与功能重点实验室
新药研究国家重点实验室
通讯作者Deng, Fei
作者单位1.Chinese Acad Sci, State Key Lab Drug Res, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China;
2.NW A&F Univ, Coll Life Sci, Yangling 712100, Peoples R China
推荐引用方式
GB/T 7714		 Deng, Fei,Lu, Jin Jian,Liu, Hong Ying,et al. Synthesis and antitumor activity of novel salvicine analogues[J]. CHINESE CHEMICAL LETTERS,2011,22(1):25-28.
APA Deng, Fei,Lu, Jin Jian,Liu, Hong Ying,Lin, Li Ping,Ding, Jian,&Zhang, Jin Sheng.(2011).Synthesis and antitumor activity of novel salvicine analogues.CHINESE CHEMICAL LETTERS,22(1),25-28.
MLA Deng, Fei,et al."Synthesis and antitumor activity of novel salvicine analogues".CHINESE CHEMICAL LETTERS 22.1(2011):25-28.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。